Maze Therapeutics, Inc. — Form 4
Filed September 4, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 49/100
What the filing says
President, R&D & CMO Bernstein Harold (MAZE) sold 10K shares (~$270K) on the open market (51% of holdings). Large sale — ~51% of holdings.
Why this rating
Large sale — ~51% of holdings.
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.